JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

Search

Crinetics Pharmaceuticals Inc

Abierto

SectorSanidad

40.19 -0.64

Resumen

Variación precio

24h

Actual

Mínimo

39.79

Máximo

41.05

Métricas clave

By Trading Economics

Ingresos

-19M

-116M

Ventas

670K

1M

Margen de beneficios

-11,216.004

Empleados

437

EBITDA

-19M

-129M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+99.36% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.4B

4B

Apertura anterior

40.83

Cierre anterior

40.19

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct 2025, 21:20 UTC

Ganancias

Correction to IBM 3Q Sales Jump Article

22 oct 2025, 20:57 UTC

Ganancias

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 oct 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:38 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:15 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct 2025, 22:28 UTC

Charlas de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct 2025, 22:02 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct 2025, 21:47 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct 2025, 21:46 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct 2025, 21:28 UTC

Charlas de Mercado
Ganancias

Correction to Alcoa Tariff Market Talk

22 oct 2025, 21:25 UTC

Ganancias

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct 2025, 21:17 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

22 oct 2025, 20:59 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 20:51 UTC

Ganancias

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 oct 2025, 20:44 UTC

Ganancias

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparación entre iguales

Cambio de precio

Crinetics Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

99.36% repunte

Estimación a 12 Meses

Media 80.6 USD  99.36%

Máximo 143 USD

Mínimo 40 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

15

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

30.39 / 33.46Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

168 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat